Wonbiogen원바이오젠
307280 · KOSDAQ · ₩307280 · 원바이오젠
₩5,500▼ ₩120 (2.14%)End-of-day · Oct 30, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 51.9% | 50.5% | 46.9% | 47.9% | 46.6% | 42.9% |
| Operating margin | 24.9% | 22.5% | 21.0% | 24.1% | 19.3% | 11.5% |
| Net margin | 22.3% | 18.8% | 18.7% | 18.6% | 12.2% | −3.7% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +7.3% | +15.8% | +2.8% | +10.7% | +50.9% | — |
| Operating income growth | +18.6% | +23.7% | −10.1% | +38.3% | +152.5% | — |
| Net income growth | +27.3% | +16.3% | +3.5% | +68.0% | +596.0% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 19.3% | 16.6% | 16.4% | 18.6% | 12.3% | −2.5% |
| Return on assets | 15.4% | 14.5% | 12.7% | 14.6% | 8.5% | −1.7% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 20.6% | 11.7% | 10.7% | 31.5% | 45.1% | 43.2% |
| Net debt to equity | −16.0% | −35.0% | −27.3% | −5.4% | −9.2% | −25.8% |
| Current ratio | 324.8% | 600.1% | 654.9% | 226.1% | 157.2% | 210.0% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Wonbiogen / 원바이오젠 / 307280 / KRX:307280
Source: KRX statistical information